162 related articles for article (PubMed ID: 33088323)
1. Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies.
Hashemi S; Sharifi A; Zareei S; Mohamedi G; Biglar M; Amanlou M
Res Pharm Sci; 2020 Jun; 15(3):226-240. PubMed ID: 33088323
[TBL] [Abstract][Full Text] [Related]
2. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
3. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
Mouhcine M; Kadil Y; Rahmoune I; Filali H
Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
[TBL] [Abstract][Full Text] [Related]
4. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
5. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays.
Ghufran M; Rehman AU; Ayaz M; Ul-Haq Z; Uddin R; Azam SS; Wadood A
J Biomol Struct Dyn; 2023; 41(16):8053-8067. PubMed ID: 36184737
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations.
Rafiq H; Hu J; Hakami MA; Hazazi A; Alamri MA; Alkhatabi HA; Mahmood A; Alotaibi BS; Wadood A; Huang X
Sci Rep; 2023 Nov; 13(1):20147. PubMed ID: 37978263
[TBL] [Abstract][Full Text] [Related]
9. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.
Tayubi IA; Madar IH
Comput Biol Med; 2023 Jan; 152():106377. PubMed ID: 36493736
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking analysis of KRAS inhibitors for cancer management.
J Hakeem I; Alsharif FH; Aljadani M; Fahad Alabbas I; Faqihi MS; Aloufi AH; Almutairi WA; Akber AH; Alam Q
Bioinformation; 2023; 19(4):411-416. PubMed ID: 37822837
[TBL] [Abstract][Full Text] [Related]
13. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Mishra A; Rathore AS
Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
[TBL] [Abstract][Full Text] [Related]
15. CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.
Durojaye OA; Ejaz U; Uzoeto HO; Fadahunsi AA; Opabunmi AO; Ekpo DE; Sedzro DM; Idris MO
Amino Acids; 2023 Dec; 55(12):1745-1764. PubMed ID: 37500789
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore-based virtual screening and
Roney M; Huq AKMM; Issahaku AR; Soliman MES; Hossain MS; Mustafa AH; Islam MA; Dubey A; Tufail A; Mohd Aluwi MFF; Tajuddin SN
J Biomol Struct Dyn; 2023; 41(21):12186-12203. PubMed ID: 36645141
[TBL] [Abstract][Full Text] [Related]
17. mPGES-1 Inhibitor Discovery Based on Computer-Aided Screening: Pharmacophore Models, Molecular Docking, ADMET, and MD Simulations.
Huang Q; Lai T; Wang Q; Luo L
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630311
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore Modelling and Virtual Screening Studies for the Discovery of Potential Natural Products Based PDE1B Inhibitor Lead Compounds.
Shy TW; Gaurav A
Cent Nerv Syst Agents Med Chem; 2021; 21(3):195-204. PubMed ID: 34970959
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel tubulin inhibitors targeting taxanes site by virtual screening, molecular dynamic simulation, and biological evaluation.
Zhang H; Mao J; Yang YL; Liu CT; Shen C; Zhang HR; Xie HZ; Ding L
J Cell Biochem; 2021 Nov; 122(11):1609-1624. PubMed ID: 34237164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
